Role and place of PARP inhibitors in the modern treatment algorithm of BRCA-associated HER2-negative metastatic breast cancer. Results of the educational and discussion events based on the “OncoForum” platform

In 2020, within the framework of the educational project Talisman on BRCA-associated HER2-negative metastatic breast cancer (mBC), Pfizer with the support of TS Oncology held 4 educational and discussion events based on the OncoForum platform (virtual-platform developed and operated by TS Oncology)....

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Editorial Board
Formato:	article
Lenguaje:	RU
Publicado:	IP Habib O.N. 2021
Materias:	gbrca1/2-mutated her2-negative metastatic breast cancer genetic diagnostics of germline brca mutations guidelines parp-inhibitors talazoparib Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/a4689c9b2791416c91a1d1c44c46a999
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a4689c9b2791416c91a1d1c44c46a999
record_format	dspace
spelling	oai:doaj.org-article:a4689c9b2791416c91a1d1c44c46a9992021-11-30T16:55:00ZRole and place of PARP inhibitors in the modern treatment algorithm of BRCA-associated HER2-negative metastatic breast cancer. Results of the educational and discussion events based on the “OncoForum” platform1815-14341815-144210.26442/18151434.2021.1.200707https://doaj.org/article/a4689c9b2791416c91a1d1c44c46a9992021-05-01T00:00:00Zhttps://modernonco.orscience.ru/1815-1434/article/viewFile/70288/51217https://doaj.org/toc/1815-1434https://doaj.org/toc/1815-1442In 2020, within the framework of the educational project Talisman on BRCA-associated HER2-negative metastatic breast cancer (mBC), Pfizer with the support of TS Oncology held 4 educational and discussion events based on the OncoForum platform (virtual-platform developed and operated by TS Oncology). 44 key specialists from federal and regional cancer centers representing 7 federal districts took part in these events and shared their opinion on the current state of availability of molecular genetic research for germline mutations in BRCA genes and treatment approaches of BRCA-associated HER2-negative mBC in Russia. The results of these interactive discussions are represented in the current overview.Editorial BoardIP Habib O.N.articlegbrca1/2-mutated her2-negative metastatic breast cancergenetic diagnostics of germline brca mutationsguidelinesparp-inhibitorstalazoparibNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282RUСовременная онкология, Vol 23, Iss 1, Pp 45-47 (2021)
institution	DOAJ
collection	DOAJ
language	RU
topic	gbrca1/2-mutated her2-negative metastatic breast cancer genetic diagnostics of germline brca mutations guidelines parp-inhibitors talazoparib Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	gbrca1/2-mutated her2-negative metastatic breast cancer genetic diagnostics of germline brca mutations guidelines parp-inhibitors talazoparib Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Editorial Board Role and place of PARP inhibitors in the modern treatment algorithm of BRCA-associated HER2-negative metastatic breast cancer. Results of the educational and discussion events based on the “OncoForum” platform
description	In 2020, within the framework of the educational project Talisman on BRCA-associated HER2-negative metastatic breast cancer (mBC), Pfizer with the support of TS Oncology held 4 educational and discussion events based on the OncoForum platform (virtual-platform developed and operated by TS Oncology). 44 key specialists from federal and regional cancer centers representing 7 federal districts took part in these events and shared their opinion on the current state of availability of molecular genetic research for germline mutations in BRCA genes and treatment approaches of BRCA-associated HER2-negative mBC in Russia. The results of these interactive discussions are represented in the current overview.
format	article
author	Editorial Board
author_facet	Editorial Board
author_sort	Editorial Board
title	Role and place of PARP inhibitors in the modern treatment algorithm of BRCA-associated HER2-negative metastatic breast cancer. Results of the educational and discussion events based on the “OncoForum” platform
title_short	Role and place of PARP inhibitors in the modern treatment algorithm of BRCA-associated HER2-negative metastatic breast cancer. Results of the educational and discussion events based on the “OncoForum” platform
title_full	Role and place of PARP inhibitors in the modern treatment algorithm of BRCA-associated HER2-negative metastatic breast cancer. Results of the educational and discussion events based on the “OncoForum” platform
title_fullStr	Role and place of PARP inhibitors in the modern treatment algorithm of BRCA-associated HER2-negative metastatic breast cancer. Results of the educational and discussion events based on the “OncoForum” platform
title_full_unstemmed	Role and place of PARP inhibitors in the modern treatment algorithm of BRCA-associated HER2-negative metastatic breast cancer. Results of the educational and discussion events based on the “OncoForum” platform
title_sort	role and place of parp inhibitors in the modern treatment algorithm of brca-associated her2-negative metastatic breast cancer. results of the educational and discussion events based on the “oncoforum” platform
publisher	IP Habib O.N.
publishDate	2021
url	https://doaj.org/article/a4689c9b2791416c91a1d1c44c46a999
work_keys_str_mv	AT editorialboard roleandplaceofparpinhibitorsinthemoderntreatmentalgorithmofbrcaassociatedher2negativemetastaticbreastcancerresultsoftheeducationalanddiscussioneventsbasedontheoncoforumplatform
_version_	1718406462886117376

Role and place of PARP inhibitors in the modern treatment algorithm of BRCA-associated HER2-negative metastatic breast cancer. Results of the educational and discussion events based on the “OncoForum” platform

Ejemplares similares